Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 20, 2022
Daily News
July 20, 2022
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- MHLW Official Sees More “Specified Clinical Research” Data Used in Regulatory Submissions to Fill Industry-Academia Void
July 20, 2022
- PMDA Head Fujiwara Re-Elected as ICMRA Vice Chair
July 20, 2022
- Healios to Raise 2.9 Billion Yen for R&D of eNK Cells
July 20, 2022
- Ono Sets Up Venture Capital Unit to Invest in Digital Health
July 20, 2022
- Opdivo Approved in Taiwan for Frontline Esophageal Cancer Use
July 20, 2022
- Enhertu Gets 2nd Line Breast Cancer Nod in Europe: Daiichi Sankyo
July 20, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…